There is a serious worldwide shortage of recombinant factor VIII, a critical blood-clotting protein that hemophilic patients use to prevent and control their bleeds, according to the National ...

Authorizing FDA to approve abbreviated BLAs for recombinant factor VIII (FVIII) and recombinant factor IX (FIX) would drastically increase these costs because, according to the European Medicines ...

Closer to market is Sobi-partnered efanesoctocog alfa (also known as BIVV001), an engineered recombinant Factor VIII designed to sustain high protection from bleeds in people with haemophilia A ...

Am J Health Syst Pharm. 2006;63(17):1641-1646. Our institution, the University of Virginia Health System (UVHS), added factor VIIa (recombinant) to its formulary on August 27, 1999. Informal ...

Some products are harvested from humans or animals, and some are manufactured by using recombinant technology. Antihemophilic factor (AHF, or factor VIII), factor IX, factor VIIa, factor IX ...

Whereas early recombinant products approved were invariably replacement proteins, displaying amino acid sequences identical to the native human molecule (e.g., human insulin, Factor VIII ...